Navigation Links
Avalon Pharmaceuticals names lead development candidate in beta-catenin inhibitor program
Date:6/26/2008

Germantown, MD, June 26, 2008 -- Avalon Pharmaceuticals, Inc. (Nasdaq: AVRX), announced today the nomination of AVN316 as a lead clinical development candidate in its Beta-catenin Pathway Inhibitor program. This novel compound inhibits the Beta-catenin pathway and is a potent inducer of cancer cell death. The Company plans to begin clinical testing of AVN316 in patients in 2009.

Beta-catenin is one of the most commonly activated cancer pathways and is known to play a key role in the initiation and progression of cancer. The Beta-catenin pathway is upregulated in a large number of different cancer types, in particular colon cancer, where it has been estimated to be abnormally activated in at least 90 percent of cases.

"The biological complexity and the classically intractable nature of the beta-catenin protein have prevented this pathway from being effectively targeted by conventional drug discovery techniques, despite the efforts of numerous pharmaceutical companies," stated Kenneth Carter, Ph.D., President and CEO of Avalon Pharmaceuticals, Inc. "We are very pleased to name AVN316 as the lead compound for this intractable target, which we believe provides validation for our unique drug discovery platform, AvalonRx."

Using AvalonRx, the Company identified several chemical compounds series that inhibit beta-catenin function. One family of structurally distinct chemical compounds potently down-regulate the Beta-catenin pathway by reducing beta-catenin protein levels. This lead compound series (of which AVN316 is a member) decreases the beta-catenin protein levels in cancer cells and xenograft tumors, induces biomarkers of Beta-catenin pathway inhibition, and inhibits tumor growth. AVN316 was chosen from the series for its potency and tumor growth inhibition properties in animal models of human disease. Near-term activities with AVN316 include toxicology studies and large-scale manufacturing in preparation for IND submission
'/>"/>

Contact: Kate Gormley
kgormley@dorland.com
215-928-2720
Dorland Global Public Relations
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... State University Spokane have developed a new way ... off behind the wheel. , Their recently patented ... more variable in drowsy driversand offers an affordable ... driver drowsiness detection systems. , Van Dongen"Video-based systems ... is drifting out of its lane are cumbersome ...
(Date:4/23/2014)... University researcher is looking to give exercise enthusiasts the ... latest research shows that a cyber buddy can help. ... for Health Journal , is the first to indicate ... motivator during exercise, a software-generated partner also can be ... isn,t real can still motivate people to give greater ...
(Date:4/23/2014)... rats exposed to high-energy particles, simulating conditions astronauts would ... in attention and slower reaction times, even when the ... The cognitive impairments which affected a large subset, ... to be linked to protein changes in the brain, ... true in humans, suggest it may be possible to ...
(Date:4/23/2014)... researchers have identified an important enzyme pathway that helps ... few chromosomes, a condition that has been directly linked ... professor of biochemistry, found that near the end of ... that ensures any breaks in DNA are fully repaired ... to daughter cells. This process helps safeguard against some ...
(Date:4/23/2014)... has long been considered to be between 180 and ... used refined microscopic techniques that indicate a much smaller ... tract is only as large as a normal studio ... which passes from the mouth through the esophagus and ... 5 meters in a normal adult, and is built ...
Breaking Medicine News(10 mins):Health News:WSU innovation improves drowsy driver detection 2Health News:Cyber buddy is better than 'no buddy' 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2
... THE MARKET FORECAST FOR THE DRUG, WALTHAM, Mass., ... Resources, is available to discuss the impact of the ... the,first integrase inhibitor drug which blocks the ability of ... Integrase inhibitors are a novel class of HIV drugs ...
... New products, a growing world,population expected to ... as the,aging of that population, will push anesthesia ... according to Anesthesia Drugs: Worldwide Markets, a,new report ... surgical procedures required anesthetic,administration worldwide in 2006, and ...
... SYK ) disclosed today that the United ... inquiry of the Company regarding possible,violations of the ... sale,of medical devices in certain foreign countries. Stryker ... Commission regarding this,informal investigation. Stryker Corporation is ...
... 118 patients with portal vein thrombosis, noncirrhotic and nontumoral ... well tolerated bleed. Cirrhosis and tumor related portal vein ... state as a cause of portal vein thrombosis is ... number of patients. , A research article to be ...
... health information program recognized for helping to reduce, ... self-care., INDIANAPOLIS, Oct. 12 WellPoint NextRx, ... has received a 2007,Disease Management Leadership Award from ... innovative, Web-based Health Envelope(R) Program.,WellPoint NextRx is owned ...
... /Xinhua-PRNewswire-FirstCall/ -- China,Medicine Corporation ("CMC") (OTC ... prescription and over the counter pharmaceutical ... of Chinese herbs),Chinese herbs, nutritional supplements, ... today announced the Company,s ADTZ,(Aflatoxin-detoxifizyme) project ...
Cached Medicine News:Health News:Impending FDA Approval Decision on the First HIV Integrase Inhibitor Can Have Significant Impact for Patients 2Health News:Anesthesia Drugs Market to Grow to $4.3 Billion by 2011 as Populations and Uses for Anesthesia Increase 2Health News:Portal vein thrombosis is common in extraportal vein obstruction 2Health News:WellPoint NextRx Receives National Leadership Award for Innovative Web Tool 2Health News:WellPoint NextRx Receives National Leadership Award for Innovative Web Tool 3Health News:China Medicine's ADTZ Project Has Been Selected as One of Six Patent Commercialization Projects in Guangdong Province 2
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Global ... Systems -- Focus on End Users ... OBJECTIVES A drug delivery system ...
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, Inc ... of less invasive, miniaturized circulatory support technologies that are ... that it expects revenues for the fourth quarter of ... 2013 revenues to approximately $208 million. "Our ...
(Date:1/14/2014)... HARRISBURG, Pa. , Jan. 14, 2014 Dynamic Healthcare ... ("GMH"), announced today that it acquired Progressive Home Medical Equipment, ... January 7, 2014. The terms of the acquisition were not ... medical equipment ("DME") company providing a wide range of sleep, ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... April 13, 2011 Cephalon, Inc. (Nasdaq: ... CXS Holdings Pty Ltd (Cephalon), has lodged the offer ... for ChemGenex Pharmaceuticals Limited (ASX: CXS) (ChemGenex) with the ... offering a 58 percent premium to the one-month volume ...
... Pharmaceuticals, Inc., the leader in the development of neurosteroids ... of a $3 million grant by the U.S. Department ... the treatment of Fragile-X Syndrome (FXS). Ganaxolone modulates GABA-A ... Early research suggests that normalizing neurosteroid levels with ganaxolone ...
Cached Medicine Technology:Cephalon Lodges Bidder's Statement for A$167 Million Offer for ChemGenex Pharmaceuticals 2Cephalon Lodges Bidder's Statement for A$167 Million Offer for ChemGenex Pharmaceuticals 3Marinus Pharmaceuticals Announces U.S. Department of Defense Grant to Study Ganaxolone in Fragile-X Syndrome 2
Tube for Right Bronchus - Ruschelit™ PVC. Color coded for easy identification of ports, balloons and 15mm connectors. High volume/low pressure cuffs. With Carina hook. X-ray opaque line. Gradua...
Laser resistant tubes for use with CO2 and KTP Lasers., ,Designed for airway management during laser surgery of the larynx or other areas in close proximity to the trachea....
Laryngectomy Tubes with special J-shape for convenient placement through a tracheostomy stoma....
SPIRAL-FLEX® Reinforced Oral/Nasal Cuffed Endotracheal Tubes...
Medicine Products: